Back to results
US 12,559,535 B2Granted
Method for the in vitro differentiation and maturation of dendritic cells for therapeutic use
AssigneeUniversiteit Gent
InventorKarim Vermaelen
Life of this patent
Estimating the term…
Abstract
The present invention relates to an accelerated method to generate high yields of type-1 polarizing mRNA loaded dendritic cells for use in immunotherapy, and in particular for use in cancer vaccination.
Claims24
A method for manufacturing mature, clinical grade autologous dendritic cells (DCs), said method comprising:
- culturing dendritic cell precursors for about 48 to 96 hours in a closed culture system in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4);
- contacting the immature DCs for the last 20 to 28 hours of the culturing step with Interferon gamma (IFN-g) and monophosphoryl lipid A (MPLA), under culture conditions suitable for maturation of the immature DCs to form a mature DC population;
- harvesting the mature DCs;
- and
- transfecting the mature DCs with antigen-encoding mRNA before or after harvest of the mature DCs.
2 more elements
Mature dendritic cells obtained by a method comprising the following steps:
- culturing dendritic cell precursors for about 48 to 96 hours in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4);
- contacting the immature DCs for the last 20 to 28 hours of the culturing step with Interferon gamma (IFN-g) and monophosphoryl lipid A (MPLA), under culture conditions suitable for maturation of the immature DCs to form a mature DC population;
- harvesting the mature DCs;
- and
- transfecting the mature DCs with antigen-encoding mRNA before or after harvest of the mature DCs.
2 more elements
Dependencies are inferred from the claim text.